Nuo Therapeutics, Inc. (AURX)
USD 1.35
(-1.46%)
USD 1.35
(-1.46%)
| Year | Total Assets | Total Assets Growth |
|---|---|---|
| 2023 | 1.87 Million USD | -38.38% |
| 2022 | 3.04 Million USD | 1932.52% |
| 2021 | 149.93 Thousand USD | -2.06% |
| 2020 | 153.08 Thousand USD | -2.66% |
| 2019 | 157.26 Thousand USD | -83.88% |
| 2018 | 975.49 Thousand USD | -31.5% |
| 2017 | 1.42 Million USD | -90.19% |
| 2016 | 14.51 Million USD | 105.14% |
| 2015 | 7.07 Million USD | -87.42% |
| 2014 | 56.22 Million USD | 21.56% |
| 2013 | 46.25 Million USD | 4.33% |
| 2012 | 44.33 Million USD | 339.86% |
| 2011 | 10.07 Million USD | 13.24% |
| 2010 | 8.9 Million USD | 243.37% |
| 2009 | 2.59 Million USD | -45.98% |
| 2008 | 4.79 Million USD | -52.12% |
| 2007 | 10.02 Million USD | -2.07% |
| 2006 | 10.23 Million USD | 29.9% |
| 2005 | 7.87 Million USD | -3.77% |
| 2004 | 8.18 Million USD | 42.6% |
| 2003 | 5.74 Million USD | -6.71% |
| 2002 | 6.15 Million USD | 419.79% |
| 2001 | 1.18 Million USD | -69.45% |
| 2000 | 3.87 Million USD | 1294.22% |
| 1999 | 277.95 Thousand USD | 0.0% |
| Year | Total Assets | Total Assets Growth |
|---|---|---|
| 2024 Q2 | 1.42 Million USD | 14.29% |
| 2024 Q1 | 1.24 Million USD | -33.82% |
| 2023 Q3 | 1.59 Million USD | 15.49% |
| 2023 Q1 | 2.22 Million USD | -27.12% |
| 2023 Q2 | 1.38 Million USD | -37.62% |
| 2023 FY | 1.87 Million USD | -38.38% |
| 2023 Q4 | 1.87 Million USD | 17.37% |
| 2022 Q2 | 4.32 Million USD | 308.54% |
| 2022 FY | 3.04 Million USD | 1932.52% |
| 2022 Q4 | 3.04 Million USD | -21.15% |
| 2022 Q3 | 3.86 Million USD | -10.6% |
| 2022 Q1 | 1.05 Million USD | 605.8% |
| 2021 Q1 | - USD | -100.0% |
| 2021 Q3 | 149.93 Thousand USD | 0.0% |
| 2021 Q4 | 149.93 Thousand USD | 0.0% |
| 2021 FY | 149.93 Thousand USD | -2.06% |
| 2020 Q4 | 153.08 Thousand USD | 0.0% |
| 2020 FY | 153.08 Thousand USD | -2.66% |
| 2019 Q4 | 157.26 Thousand USD | 308.53% |
| 2019 FY | 157.26 Thousand USD | -83.88% |
| 2019 Q1 | 461.4 Thousand USD | -52.7% |
| 2019 Q2 | 154.33 Thousand USD | -66.55% |
| 2019 Q3 | 38.49 Thousand USD | -75.06% |
| 2018 Q1 | 972.74 Thousand USD | -31.69% |
| 2018 Q4 | 975.49 Thousand USD | 28.38% |
| 2018 Q2 | 823.32 Thousand USD | -15.36% |
| 2018 Q3 | 759.83 Thousand USD | -7.71% |
| 2018 FY | 975.49 Thousand USD | -31.5% |
| 2017 Q3 | 10.21 Million USD | 15.54% |
| 2017 FY | 1.42 Million USD | -90.19% |
| 2017 Q1 | 12.42 Million USD | -14.4% |
| 2017 Q2 | 8.83 Million USD | -28.83% |
| 2017 Q4 | 1.42 Million USD | -86.06% |
| 2016 FY | 14.51 Million USD | 105.14% |
| 2016 Q2 | 19.6 Million USD | 183.91% |
| 2016 Q4 | 14.51 Million USD | -13.36% |
| 2016 Q3 | 16.74 Million USD | -14.55% |
| 2016 Q1 | 6.9 Million USD | -2.4% |
| 2015 Q2 | 46.46 Million USD | -11.89% |
| 2015 FY | 7.07 Million USD | -87.42% |
| 2015 Q1 | 52.73 Million USD | -6.2% |
| 2015 Q4 | 7.07 Million USD | -63.07% |
| 2015 Q3 | 19.15 Million USD | -58.78% |
| 2014 Q2 | 65.33 Million USD | 30.04% |
| 2014 Q3 | 60.25 Million USD | -7.77% |
| 2014 Q4 | 56.22 Million USD | -6.69% |
| 2014 FY | 56.22 Million USD | 21.56% |
| 2014 Q1 | 50.24 Million USD | 8.62% |
| 2013 Q3 | 46.89 Million USD | 0.68% |
| 2013 Q2 | 46.57 Million USD | -8.28% |
| 2013 FY | 46.25 Million USD | 4.33% |
| 2013 Q4 | 46.25 Million USD | -1.36% |
| 2013 Q1 | 50.77 Million USD | 14.54% |
| 2012 FY | 44.33 Million USD | 339.86% |
| 2012 Q2 | 50.39 Million USD | 2.12% |
| 2012 Q4 | 44.33 Million USD | -6.75% |
| 2012 Q1 | 49.34 Million USD | 389.65% |
| 2012 Q3 | 47.53 Million USD | -5.67% |
| 2011 Q2 | 7.96 Million USD | -10.08% |
| 2011 Q4 | 10.07 Million USD | 11.41% |
| 2011 FY | 10.07 Million USD | 13.24% |
| 2011 Q1 | 8.85 Million USD | -0.49% |
| 2011 Q3 | 9.04 Million USD | 13.59% |
| 2010 FY | 8.9 Million USD | 243.37% |
| 2010 Q1 | 1.6 Million USD | -38.13% |
| 2010 Q2 | 8.72 Million USD | 443.91% |
| 2010 Q3 | 9.08 Million USD | 4.2% |
| 2010 Q4 | 8.9 Million USD | -2.08% |
| 2009 Q4 | 2.59 Million USD | -28.75% |
| 2009 Q1 | 3.8 Million USD | -20.6% |
| 2009 FY | 2.59 Million USD | -45.98% |
| 2009 Q3 | 3.63 Million USD | 21.02% |
| 2009 Q2 | 3 Million USD | -21.1% |
| 2008 Q1 | 9.36 Million USD | -6.55% |
| 2008 Q4 | 4.79 Million USD | -48.0% |
| 2008 Q2 | 8.47 Million USD | -9.51% |
| 2008 FY | 4.79 Million USD | -52.12% |
| 2008 Q3 | 9.22 Million USD | 8.88% |
| 2007 Q2 | 8.98 Million USD | -5.24% |
| 2007 Q4 | 10.02 Million USD | 17.93% |
| 2007 FY | 10.02 Million USD | -2.07% |
| 2007 Q1 | 9.48 Million USD | -7.31% |
| 2007 Q3 | 8.49 Million USD | -5.46% |
| 2006 Q3 | 10.26 Million USD | -4.75% |
| 2006 FY | 10.23 Million USD | 29.9% |
| 2006 Q1 | 7.02 Million USD | -10.83% |
| 2006 Q2 | 10.77 Million USD | 53.46% |
| 2006 Q4 | 10.23 Million USD | -0.33% |
| 2005 FY | 7.87 Million USD | -3.77% |
| 2005 Q3 | 8.74 Million USD | -2.22% |
| 2005 Q2 | 8.94 Million USD | 0.76% |
| 2005 Q1 | 8.87 Million USD | 8.45% |
| 2005 Q4 | 7.87 Million USD | -9.94% |
| 2004 Q3 | 8.1 Million USD | -5.5% |
| 2004 Q4 | 8.18 Million USD | 0.97% |
| 2004 Q1 | 9.76 Million USD | 70.03% |
| 2004 FY | 8.18 Million USD | 42.6% |
| 2004 Q2 | 8.57 Million USD | -12.1% |
| 2003 Q2 | 6.05 Million USD | 8.74% |
| 2003 Q1 | 5.56 Million USD | -9.57% |
| 2003 FY | 5.74 Million USD | -6.71% |
| 2003 Q4 | 5.74 Million USD | -14.89% |
| 2003 Q3 | 6.74 Million USD | 11.47% |
| 2002 Q4 | 6.15 Million USD | -15.3% |
| 2002 Q2 | 5 Million USD | 313.46% |
| 2002 Q3 | 7.26 Million USD | 45.31% |
| 2002 FY | 6.15 Million USD | 419.79% |
| 2002 Q1 | 1.2 Million USD | 2.15% |
| 2001 Q4 | 1.18 Million USD | 11.44% |
| 2001 Q2 | 1.75 Million USD | -80.51% |
| 2001 Q3 | 1.06 Million USD | -39.49% |
| 2001 Q1 | 9 Million USD | 132.48% |
| 2001 FY | 1.18 Million USD | -69.45% |
| 2000 FY | 3.87 Million USD | 1294.22% |
| 2000 Q4 | 3.87 Million USD | -28.97% |
| 2000 Q3 | 5.45 Million USD | -17.24% |
| 2000 Q2 | 6.59 Million USD | -14.52% |
| 2000 Q1 | 7.71 Million USD | 0.0% |
| 1999 FY | 277.95 Thousand USD | 0.0% |
| Name | Total Assets | Total Assets Difference |
|---|---|---|
| Burzynski Research Institute, Inc. | 2310.00 USD | -81193.506% |
| Arch Therapeutics, Inc. | 1.95 Million USD | 4.101% |
| Evofem Biosciences, Inc. | 10.55 Million USD | 82.207% |
| Nascent Biotech, Inc. | 552.12 Thousand USD | -240.122% |
| Rebus Holdings, Inc. | 5000.00 USD | -37457.6% |
| Santhera Pharmaceuticals Holding AG | 130.21 Million USD | 98.558% |
| Qrons Inc. | 420.00 USD | -447014.286% |
| Adynxx, Inc. | - USD | -Infinity% |
| Neon Bloom, Inc. | 770.64 Thousand USD | -143.677% |
| Northwest Biotherapeutics, Inc. | 27.94 Million USD | 93.28% |
| ProtoKinetix, Incorporated | 480.55 Thousand USD | -290.772% |
| Skye Bioscience, Inc. | 11.94 Million USD | 84.273% |
| Eiger BioPharmaceuticals, Inc. | 38.84 Million USD | 95.166% |
| Nanobac Pharmaceuticals, Incorporated | 7.21 Million USD | 73.99% |
| Institute of Biomedical Research Corp. | 76.35 Thousand USD | -2359.439% |
| SQZ Biotechnologies Company | 107.18 Million USD | 98.248% |
| Intellipharmaceutics International Inc. | 1.43 Million USD | -31.134% |
| Propanc Biopharma, Inc. | 72.36 Thousand USD | -2495.011% |
| Mesoblast Limited | 667.9 Million USD | 99.719% |
| Marizyme, Inc. | 22.01 Million USD | 91.47% |
| Genus plc | 1.02 Billion USD | 99.817% |
| VioQuest Pharmaceuticals, Inc. | 1.35 Million USD | -38.247% |
| Pharming Group N.V. | 462.85 Million USD | 99.594% |
| Therapeutic Solutions International, Inc. | 3.31 Million USD | 43.318% |
| CNBX Pharmaceuticals Inc. | 499.03 Thousand USD | -276.299% |
| Nymox Pharmaceutical Corporation | 627 Thousand USD | -199.502% |
| ContraFect Corporation | 20.67 Million USD | 90.919% |
| PsyBio Therapeutics Corp. | 390.36 Thousand USD | -381.056% |
| Sienna Biopharmaceuticals, Inc. | - USD | -Infinity% |
| RegeneRx Biopharmaceuticals, Inc. | 382.17 Thousand USD | -391.364% |
| IMV Inc. | 31.33 Million USD | 94.007% |
| AXIM Biotechnologies, Inc. | 4.14 Million USD | 54.706% |
| MultiCell Technologies, Inc. | 126.22 USD | -1487683.236% |
| ONE Bio Corp. | 70.08 Million USD | 97.321% |
| Accustem Sciences Inc. | 939.68 Thousand USD | -99.841% |
| RVL Pharmaceuticals plc | 128.51 Million USD | 98.539% |
| Arno Therapeutics, Inc. | - USD | -Infinity% |
| EV Biologics, Inc. | 431.71 Thousand USD | -334.982% |
| Q BioMed Inc. | 3.51 Million USD | 46.583% |
| Emmaus Life Sciences, Inc. | 35.17 Million USD | 94.662% |
| Mosaic ImmunoEngineering Inc. | 261.27 Thousand USD | -618.731% |
| Biomind Labs Inc. | 73.81 Thousand USD | -2443.898% |
| American Oriental Bioengineering, Inc. | 446.3 Million USD | 99.579% |
| Provectus Biopharmaceuticals, Inc. | 1.44 Million USD | -29.612% |
| TetraLogic Pharmaceuticals Corporation | - USD | -Infinity% |
| Oncotelic Therapeutics, Inc. | 30.01 Million USD | 93.744% |
| GlobeStar Therapeutics Corporation | - USD | -Infinity% |
| THC Farmaceuticals, Inc. | 2.74 Million USD | 31.622% |
| Acro Biomedical Co., Ltd. | 687.48 Thousand USD | -173.152% |
| Curative Biotechnology, Inc. | 2.6 Million USD | 27.863% |
| GB Sciences, Inc. | 103.44 Thousand USD | -1715.394% |
| Alpha Cognition Inc. | 2.45 Million USD | 23.42% |
| HST Global, Inc. | 1526.00 USD | -122958.978% |
| CSL Limited | 38.02 Billion USD | 99.995% |
| Wesana Health Holdings Inc. | 987.96 Thousand USD | -90.075% |
| Halberd Corporation | 10.13 Thousand USD | -18435.979% |
| Enzolytics Inc. | 361.7 Million USD | 99.481% |
| Agentix Corp. | 261.39 Thousand USD | -618.415% |
| Resverlogix Corp. | 8.11 Million USD | 76.859% |
| MetaStat, Inc. | - USD | -Infinity% |
| argenx SE | 4.54 Billion USD | 99.959% |
| Enzon Pharmaceuticals, Inc. | 47.7 Million USD | 96.063% |
| Endonovo Therapeutics, Inc. | 639.65 Thousand USD | -193.577% |
| RespireRx Pharmaceuticals Inc. | 22.78 Thousand USD | -8143.185% |
| GeneThera, Inc. | - USD | -Infinity% |
| Inhibitor Therapeutics, Inc. | 8.94 Million USD | 79.016% |
| AVAX Technologies, Inc. | 7.37 Million USD | 74.545% |
| Zenith Capital Corp. | 7410.00 USD | -25242.51% |
| Genscript Biotech Corporation | 3.38 Billion USD | 99.945% |
| Ember Therapeutics, Inc. | 184.00 USD | -1020486.957% |
| Anthera Pharmaceuticals, Inc. | - USD | -Infinity% |
| Sigyn Therapeutics, Inc. | 321.8 Thousand USD | -483.544% |
| WPD Pharmaceuticals Inc. | 261.36 Thousand USD | -618.492% |
| Cotinga Pharmaceuticals Inc. | 927.96 Thousand USD | -102.366% |
| Kadimastem Ltd | 2.3 Million USD | 18.498% |
| Helix BioMedix, Inc. | 3.02 Million USD | 37.923% |
| VitaSpring Biomedical Co. Ltd. | - USD | -Infinity% |
| Capstone Therapeutics Corp. | 52.7 Million USD | 96.437% |
| BioStem Technologies, Inc. | 14.56 Million USD | 87.103% |
| Oncology Pharma Inc. | - USD | -Infinity% |
| Reve Technologies, Inc. | 57.09 Thousand USD | -3189.102% |
| LadRx Corporation | 2.3 Million USD | 18.632% |
| Cell Source, Inc. | 195.17 Thousand USD | -862.172% |
| Regen BioPharma, Inc. | 353.61 Thousand USD | -431.049% |
| Regen BioPharma, Inc. | 353.61 Thousand USD | -431.049% |
| NovAccess Global Inc. | 62.24 Thousand USD | -2916.772% |
| Affymax, Inc. | 7.44 Million USD | 74.77% |
| Itoco Inc. | 1.4 Million USD | -34.127% |
| Rasna Therapeutics, Inc. | 95.65 Thousand USD | -1863.139% |
| Pathfinder Cell Therapy, Inc. | 106 Thousand USD | -1671.585% |
| Mobile Lads Corp. | 52.00 USD | -3611207.692% |
| CytoDyn Inc. | 11.13 Million USD | 83.137% |
| Claritas Pharmaceuticals, Inc. | - USD | -Infinity% |
| NDT Pharmaceuticals Inc. | 142.97 Thousand USD | -1213.46% |
| NanoSphere Health Sciences Inc. | 17.88 Thousand USD | -10402.685% |
| Alseres Pharmaceuticals, Inc. | 385.47 Thousand USD | -387.165% |
| SYBLEU INC | 330.46 Thousand USD | -468.249% |
| Advanced Proteome Therapeutics Corporation | - USD | -Infinity% |
| ImmunoCellular Therapeutics, Ltd. | 409.42 Thousand USD | -358.666% |
| International Stem Cell Corporation | 5.39 Million USD | 65.16% |
| Bioxytran, Inc. | 137.63 Thousand USD | -1264.362% |
| GlobeImmune, Inc. | - USD | -Infinity% |
| Predictive Technology Group, Inc. | - USD | -Infinity% |
| ProText Mobility, Inc. | 15 Million USD | 87.482% |
| Cardax, Inc. | - USD | -Infinity% |
| VG Life Sciences Inc. | - USD | -Infinity% |
| Kaleido Biosciences, Inc. | - USD | -Infinity% |
| Advaxis, Inc. | 16.57 Million USD | 88.673% |
| Adhera Therapeutics, Inc. | 79 Thousand USD | -2277.063% |
| RenovaCare, Inc. | - USD | -Infinity% |
| Regnum Corp. | 864.67 Thousand USD | -117.177% |
| Innovation Pharmaceuticals Inc. | 7.51 Million USD | 75.018% |
| Neutra Corp. | 2851.00 USD | -65767.415% |
| Windtree Therapeutics, Inc. | 32.4 Million USD | 94.205% |
| PureTech Health plc | 693.97 Million USD | 99.729% |
| Coeptis Therapeutics, Inc. | 8.07 Million USD | 76.733% |
| IXICO plc | 15.84 Million USD | 88.148% |
| IntelGenx Technologies Corp. | 8.28 Million USD | 77.326% |
| Gelesis Holdings, Inc. | 103.32 Million USD | 98.183% |
| CSL Limited | 38.02 Billion USD | 99.995% |
| Cellectis S.A. | 333.99 Million USD | 99.438% |